18 analysts have expressed a variety of opinions on Moderna (NASDAQ:MRNA) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table provides a quick ...
GlaxoSmithKline has filed a lawsuit against Moderna, claiming its mRNA vaccines infringe on GSK's patents. GSK seeks royalties for Moderna's alleged unlicensed use of its groundbreaking vaccine ...
Looking at options history for Moderna (NASDAQ:MRNA) we detected 15 trades. If we consider the specifics of each trade, it is accurate to state that 60% of the investors opened trades with bullish ...